Assessing neoadjuvant treatment response through serum human epidermal growth factor receptor 2 (HER2) dynamics
Our study confirms that reductions in sHER2 levels after C2 are a strong indicator of favorable treatment response in HER2-positive BC patients undergoing NAT. Monitoring sHER2 dynamics early in treatment can serve as a useful, non-invasive biomarker to predict pCR and may guide therapeutic decisions in clinical practice.
Authors
- Bingqiu Xiu (ORCID: https://orcid.org/0000-0002-0771-591X)
- Douwaner Liu
- Xuliren Wang (ORCID: https://orcid.org/0000-0002-8583-8819)
- Jiajian Chen (ORCID: https://orcid.org/0000-0001-9994-6354)
- Jiong Wu
- Hengyu Ren
- Weiru Chi
- Qi Zhang (ORCID: https://orcid.org/0000-0001-9916-8919)
- Ming Chen (ORCID: https://orcid.org/0000-0001-5041-9342)
- Zhibo Shao
- Li-Yi Zhang (ORCID: https://orcid.org/0000-0002-9731-4385)
- Min Xiong (ORCID: https://orcid.org/0000-0002-9134-3089)
- Zhi-Ming Shao (ORCID: https://orcid.org/0000-0002-2487-0401)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Gland Surgery
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/gs-24-432
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00